MIRA Pharmaceuticals Reports Positive Preclinical Results for Mira-55 Pain Treatment

Key Facts

1Mira-55 demonstrated no CNS side effects associated with THC or rimonabant in preclinical studies.

2The drug previously showed morphine-comparable pain relief without opioid-related risks.

3The company is preparing an Investigational New Drug (IND) submission for inflammatory pain.

MIRA Pharmaceuticals (NASDAQ: MIRA) has announced successful preclinical results for its lead drug candidate, Mira-55. The studies confirmed that Mira-55 provides significant pain relief without the central nervous system (CNS) side effects typically associated with THC or rimonabant. Notably, the drug had previously demonstrated analgesic efficacy comparable to morphine, yet without the high risks of addiction or respiratory depression linked to opioids. These findings represent a major milestone for the company as it seeks to develop safer, non-opioid alternatives for chronic pain management. MIRA is now actively preparing its Investigational New Drug (IND) submission to proceed with clinical trials for inflammatory pain. This progress underscores the potential of Mira-55 to address critical gaps in the traditional pain medication market.